NCT04768569View on ClinicalTrials.gov

Noise-Induced Hearing Loss-Acute Exposure Treatment

PHASE2TerminatedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

October 4, 2021

Primary Completion Date

September 29, 2023

Study Completion Date

September 29, 2023

Conditions
Hearing Loss, Noise-Induced
Interventions
DRUG

Zonisamide 100Mg Cap

ZONEGRAN® is commercially available for oral administration as capsules containing 100 mg of Zonisamide.

DRUG

Placebo

The placebo will contain microcrystalline cellulose which is the predominant filler in the generic capsule.

Trial Locations (1)

63110

Washington University School of Medicine, St Louis

Sponsors
All Listed Sponsors
collaborator

University of Texas

OTHER

collaborator

Gateway Biotechnology, Inc.

INDUSTRY

collaborator

United States Department of Defense

FED

lead

Washington University School of Medicine

OTHER